Outlook Therapeutics, Inc. (NASDAQ:OTLK) Shares Bought by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its position in shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) by 55.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,459 shares of the company’s stock after buying an additional 18,287 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Outlook Therapeutics were worth $275,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also modified their holdings of the company. AQR Capital Management LLC acquired a new position in Outlook Therapeutics during the 2nd quarter worth about $75,000. Christensen King & Associates Investment Services Inc. purchased a new stake in Outlook Therapeutics during the third quarter worth about $55,000. Squarepoint Ops LLC acquired a new stake in shares of Outlook Therapeutics during the second quarter worth about $232,000. Susquehanna Fundamental Investments LLC purchased a new position in shares of Outlook Therapeutics in the second quarter valued at approximately $303,000. Finally, Great Point Partners LLC boosted its stake in shares of Outlook Therapeutics by 15.0% in the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after purchasing an additional 221,510 shares during the period. 11.20% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Outlook Therapeutics

In related news, CFO Lawrence A. Kenyon bought 5,000 shares of the stock in a transaction dated Thursday, September 26th. The stock was acquired at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the acquisition, the chief financial officer now owns 5,946 shares in the company, valued at approximately $33,832.74. This represents a 528.54 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 3.40% of the company’s stock.

Outlook Therapeutics Trading Down 0.7 %

Shares of OTLK stock opened at $1.39 on Friday. The company has a market cap of $32.88 million, a P/E ratio of -0.13 and a beta of 0.46. The firm has a fifty day moving average price of $4.24 and a 200 day moving average price of $6.13. Outlook Therapeutics, Inc. has a 12 month low of $0.87 and a 12 month high of $12.85.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OTLK. BTIG Research cut their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 29th. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a research report on Monday, December 2nd. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Outlook Therapeutics in a report on Friday, November 29th. Finally, Ascendiant Capital Markets cut their price target on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Outlook Therapeutics has an average rating of “Moderate Buy” and an average target price of $42.34.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.